GLP-1 Peptide Atlas, by Delfa

CompletedPhase 1

A Study of LY3841136 in Overweight and Obese Participants

A Multiple Dose Combination Study to Evaluate the Safety and Tolerability of Tirzepatide and LY3841136 in Overweight and Obese Participants

Lead sponsor

Eli Lilly and Company

Assets

Eloralintide / Tirzepatide

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Obesity / overweight

Key I/E criterion

•BMI 27-45

Primary endpoint

•Serious AEs (any) (Treatment-emergent AEs (any), Serious AEs (any))

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06345066

Org study ID18834

Secondary IDJ3R-MC-YDACEli Lilly And Company

Timeline

Milestones

Study first posted2024-04-03actual

Study start2024-04-03actual

Primary completion2025-09-29actual

Study completion2025-09-29actual

Last update posted2025-10-15actual

Assets

Investigational agents

Eloralintide Tirzepatide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

Maximum age65 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Male and female participants who are overtly healthy as determined by medical evaluation

•Have a stable body weight and Body Mass Index in range of 27 to 45 kilogram per meter square (kg/m²).

•Have clinical laboratory test results within normal reference range

•Have venous access sufficient to allow for blood sampling

•Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures

Exclusion criteria

•Have type 1 or type 2 diabetes mellitus

•Have an abnormal 12-lead electrocardiogram (ECG)

•Have a history or presence of psychiatric disorders

•Have abnormal blood pressure and pulse rate

•Are currently enrolled in another clinical study trial involving medical research or have participated within the last 30 days in a clinical study involving an investigational product.

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK

Weight & body composition

1 endpoint

Secondary/protocol endpoint

Percent change from baseline in body weight

Time frame:Baseline, Week 42

Body weight, % change

percent change from baseline, improvement

Safety / tolerability / PK

3 endpoints

Primary/protocol endpoint

Number of participants with one or more Treatment Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration

Time frame:Baseline up to 42 weeks

Serious AEs (any)

event count, event

componentsTreatment-emergent AEs (any), Serious AEs (any)

Secondary/protocol endpoint

Pharmacokinetics (PK): Area Under the Concentration versus Time Curve (AUC) of LY3841136

Time frame:Predose up to 42 weeks

AUC₀–∞

concentration, descriptive

Secondary/protocol endpoint

Pharmacokinetics (PK): Maximum plasma concentration (Cmax) of LY3841136

Time frame:Predose up to 42 weeks

Cmax

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.